Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc. (BMRN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: BioMarin is a global rare disease biotechnology company focused on genetically defined conditions. The company operates with eight commercial therapies and a robust pipeline. In 2025, the company executed a significant strategic pivot, including the voluntary withdrawal of ROCTAVIAN, the acquisition of Inozyme Pharma, and the announcement of a pending acquisition of Amicus Therapeutics.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $3,221.3 million | $2,853.9 million | +12.9% |
| Net Product Revenues | $3,167.8 million | $2,809.4 million | +12.8% |
| Net Income | $348.9 million | $426.9 million | -18.3% |
| Gross Margin | 77.7% | 79.7% | -2.0 pts |
| Operating Cash Flow | $828.0 million | $572.8 million | +44.6% |
| Cash & Investments | $2,052.8 million | $1,658.9 million | +23.8% |
| Debt Obligations | $600.0 million (2027 Notes) | $600.0 million (2027 Notes) | — |
Note: Net income decreased despite revenue growth due to significant one-time charges related to restructuring and acquisitions.
Material Changes vs. Prior Period
- Revenue Growth Drivers: Total revenues increased by $367.4 million, primarily driven by strong sales of VOXZOGO (+$191.8M), PALYNZIQ (+$78.3M), and VIMIZIM (+$52.3M). This growth was partially offset by a decline in KUVAN revenues (-$21.3M) due to generic competition.
- ROCTAVIAN Withdrawal: In December 2025, the company committed to voluntarily withdraw ROCTAVIAN from the market due to lower-than-anticipated commercial opportunities. This resulted in $241.3 million in restructuring charges, including a $119.2 million inventory write-off and $118.5 million in long-lived asset impairments.
- Inozyme Acquisition: Completed in July 2025 for approximately $285 million net cash. The transaction was accounted for as an asset acquisition, resulting in a $221.0 million non-cash In-Process Research and Development (IPR&D) charge expensed in R&D.
- Amicus Acquisition Announcement: In December 2025, BioMarin agreed to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction, expected to close in Q2 2026.
- Foreign Currency Impact: A weakening of the Argentine Peso, Brazilian Real, and Mexican Peso resulted in an unfavorable impact of $40.7 million on reported product sales, partially offset by a strengthening Euro.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management expects to finance the pending Amicus acquisition through a combination of cash on hand and approximately $3.7 billion of non-convertible debt financing. In February 2026, the company issued $850 million in 5.5% senior unsecured notes due 2034, with proceeds held in escrow for the acquisition. The company anticipates entering into a senior secured term loan facility and a new revolving credit facility in 2026.
Strategic focus remains on expanding VOXZOGO indications (hypochondroplasia, idiopathic short stature, etc.) and advancing the BMN 401 pipeline asset acquired from Inozyme.
Key Risks and Contingencies
- Acquisition Risks: The Amicus acquisition is subject to regulatory clearances and shareholder approval. Failure to close or integration challenges could materially impact financial results.
- Regulatory and Pricing: The company faces ongoing pressure from government healthcare reform, including the Inflation Reduction Act (IRA) price negotiations and potential Most Favored Nation (MFN) pricing rules. EU pharmaceutical reforms may reduce data and market exclusivity periods.
- Manufacturing and Supply Chain: Reliance on single-source suppliers and third-party manufacturers poses risks of supply interruptions. The company is expanding its own manufacturing capabilities in Ireland.
- Legal Proceedings: The company is cooperating with a U.S. Department of Justice subpoena regarding sponsored testing programs for VIMIZIM and NAGLAZYME; no assurance can be given regarding the outcome.
Investor Verification Checklist
- Amicus Acquisition Financing: Verify the final terms of the $3.7 billion debt facility and the impact of the new $850 million 2034 Notes on future interest expense and leverage ratios.
- ROCTAVIAN Exit Strategy: Confirm the timeline for the complete withdrawal of ROCTAVIAN and the status of any potential out-licensing or divestiture discussions mentioned in Q4 2025.
- VOXZOGO Expansion: Monitor clinical trial progress for VOXZOGO in hypochondroplasia and other growth disorders, as these are critical for future revenue growth beyond achondroplasia.
- Generic Competition: Assess the ongoing impact of generic KUVAN on revenue and the potential for biosimilar competition for enzyme therapies (VIMIZIM, NAGLAZYME, PALYNZIQ) as patent exclusivity periods evolve.
- DOJ Investigation: Track any updates regarding the Department of Justice investigation into sponsored testing programs for VIMIZIM and NAGLAZYME.